Background: Alzheimer's disease (AD) is the primary cause of dementia, characterized by early amyloid beta accumulation, subsequent tau pathology, and eventually synaptic and neuronal loss. Sleep disturbances, a clinical phenotype in AD, are linked to amyloid beta and impaired protein clearance. However, the influence of tau pathology on sleep is less explored. Utilizing Drosophila melanogaster, we investigate the effects of adult-onset tau expression on sleep. This study addresses a knowledge gap regarding the impact of tauopathy on sleep-related changes contributing to our understanding of AD progression.

Method: We investigated the impact of adult-onset pan-neuronal expression of wildtype tau and pseudo-phosphorylated tau E14 in male and female Drosophila, induced by the gene-switch drug RU 486 (mifepristone). The flies were exposed to the inducer added to their food from 2-3 days post eclosion. Utilizing the Drosophila Activity Monitor (DAMs), we monitored activity and sleep patterns following expression for 2 weeks (n>47 flies per study group) and 4 weeks (n>17 flies per study group). Subsequently, we analysed and plotted data on activity and sleep. Additionally, at the 4-week mark, we conducted immunohistochemistry on the flies to assess neurodegeneration, and performed lifespan assays.

Result: Results consistently revealed that flies expressing tau exhibited a shorter median lifespan compared to the control group. Unexpectedly, our gene-switch control flies displayed a marked heightened activity leading to confounding behavioural effects in our analysis. Despite the activity confounds in one control line, neither the genetic controls nor the RU inducer affected sleep phenotypes, allowing investigation of sleep disruptions due to tau expression. We observe female but not male flies expressing tau have increased day sleep bouts length compared to controls. The pseudrophosphorylated E14 tau expression exacerbated/accelerated the phenotype compared to wild-type tau. Immunohistochemistry showed elevated vacuoles in tau-expressing flies indicating neurodegeneration which likely caused the sleep phenotype.

Conclusion: Our results indicate that pathological tau expression in Drosophila melanogaster causes neurodegeneration and increase sleep in females. These results indicate that pathological tau may directly contribute to sleep disruption in humans and provides a new model system to further our understanding of the role of tau in neurodegeneration.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.088411DOI Listing

Publication Analysis

Top Keywords

tau expression
16
tau
13
sleep
11
amyloid beta
8
tau pathology
8
utilizing drosophila
8
drosophila melanogaster
8
flies
8
activity sleep
8
flies study
8

Similar Publications

Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) plaques and the aggregation of tau protein, resulting in intense memory loss and dementia. Diabetes-associated cognitive dysfunction (DACD) is a complication of diabetes mellitus, which is associated with decreased cognitive function and impaired memory. A growing body of literature emphasize the involvement of microglia in AD and DACD.

View Article and Find Full Text PDF

Anti-herpetic tau preserves neurons via the cGAS-STING-TBK1 pathway in Alzheimer's disease.

Cell Rep

December 2024

School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel; Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA. Electronic address:

Alzheimer's disease (AD) diagnosis relies on the presence of extracellular β-amyloid (Aβ) and intracellular hyperphosphorylated tau (p-tau). Emerging evidence suggests a potential link between AD pathologies and infectious agents, with herpes simplex virus 1 (HSV-1) being a leading candidate. Our investigation, using metagenomics, mass spectrometry, western blotting, and decrowding expansion pathology, detects HSV-1-associated proteins in human brain samples.

View Article and Find Full Text PDF

Vascular endothelial growth factor receptor-1 (FLT1) interactions with amyloid-beta in Alzheimer's disease: A putative biomarker of amyloid-induced vascular damage.

Neurobiol Aging

December 2024

Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Pharmacology Department, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Epidemiology Doctoral Program, School of Medicine, Vanderbilt University, Nashville, TN, USA; Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

We have identified FLT1 as a protein that changes during Alzheimer's disease (AD) whereby higher brain protein levels are associated with more amyloid, more tau, and faster longitudinal cognitive decline. Given FLT1's role in angiogenesis and immune activation, we hypothesized that FLT1 is upregulated in response to amyloid pathology, driving a vascular-immune cascade resulting in neurodegeneration and cognitive decline. We sought to determine (1) if in vivo FLT1 levels (CSF and plasma) associate with biomarkers of AD neuropathology or differ between diagnostic staging in an aged cohort enriched for early disease, and (2) whether FLT1 expression interacts with amyloid on downstream outcomes, such as phosphorylated tau levels and cognitive performance.

View Article and Find Full Text PDF

Tau phosphorylation suppresses oxidative stress-induced mitophagy via FKBP8 receptor modulation.

PLoS One

January 2025

Department of Anesthesiology & Perioperative Medicine, University of Rochester, Rochester, New York, United States of America.

Neurodegenerative diseases are often characterized by mitochondrial dysfunction. In Alzheimer's disease, abnormal tau phosphorylation disrupts mitophagy, a quality control process through which damaged organelles are selectively removed from the mitochondrial network. The precise mechanism through which this occurs remains unclear.

View Article and Find Full Text PDF

Background: Applying single-cell RNA sequencing (scRNA-seq) to the study of neurodegenerative disease has propelled the field towards a more refined cellular understanding of Alzheimer's disease (AD); however, directly linking protein pathology to transcriptomic changes has not been possible at scale. Recently, a high-throughput method was developed to generate high-quality scRNA-seq data while retaining cytoplasmic proteins. Tau is a cytoplasmic protein and when hyperphosphorylated is integrally involved in AD progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!